Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Visual analog scale as a predictor of GINA-defined asthma control. The SACRA study in Japan.
Ohta K, Jean Bousquet P, Akiyama K, Adachi M, Ichinose M, Ebisawa M, Tamura G, Nagai A, Nishima S, Fukuda T, Morikawa A, Okamoto Y, Kohno Y, Saito H, Takenaka H, Grouse L, Bousquet J. Ohta K, et al. Among authors: ebisawa m. J Asthma. 2013 Jun;50(5):514-21. doi: 10.3109/02770903.2013.786726. Epub 2013 Apr 29. J Asthma. 2013. PMID: 23506422
Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, Doi S, Yamaguchi K, Katsunuma T, Kurihara K, Kondo N, Sugai K, Nambu M, Hoshioka A, Yoshihara S, Sato N, Seko N, Nishima S. Odajima H, et al. Among authors: ebisawa m. Allergol Int. 2015 Oct;64(4):364-70. doi: 10.1016/j.alit.2015.05.006. Epub 2015 Jun 10. Allergol Int. 2015. PMID: 26433533 Free article. Clinical Trial.
Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma.
Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, Doi S, Yamaguchi K, Katsunuma T, Kurihara K, Teramoto T, Sugai K, Nambu M, Hoshioka A, Yoshihara S, Sato N, Seko N, Nishima S. Odajima H, et al. Among authors: ebisawa m. Allergol Int. 2017 Jan;66(1):106-115. doi: 10.1016/j.alit.2016.06.004. Epub 2016 Aug 6. Allergol Int. 2017. PMID: 27507228 Free article. Clinical Trial.
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Arima K, Miyata M, Takahashi Y, Rice MS, Deniz Y, Rowe P, Patel N, Graham NMH, Teper A. Tohda Y, et al. Among authors: ebisawa m. Allergol Int. 2020 Oct;69(4):578-587. doi: 10.1016/j.alit.2020.04.002. Epub 2020 May 20. Allergol Int. 2020. PMID: 32444306 Free article. Clinical Trial.
Japanese guidelines for childhood asthma 2020.
Arakawa H, Adachi Y, Ebisawa M, Fujisawa T; Committee for Japanese Pediatric Guideline for Childhood Asthma; Japanese Society of Pediatric Allergy and Clinical Immunology; Japanese Society of Allergology. Arakawa H, et al. Among authors: ebisawa m. Allergol Int. 2020 Jul;69(3):314-330. doi: 10.1016/j.alit.2020.02.005. Epub 2020 Apr 25. Allergol Int. 2020. PMID: 33213779 Free article.
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study.
Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Msihid J, Djandji M, Ortiz B, Jacob-Nara JA, Deniz Y, Rowe PJ, Ishida M, Arima K. Tohda Y, et al. Among authors: ebisawa m. Allergol Int. 2023 Jan;72(1):89-99. doi: 10.1016/j.alit.2022.07.008. Epub 2022 Sep 13. Allergol Int. 2023. PMID: 36114102 Free article.
451 results